MorphoSys and Incyte announce acceptance by Health Canada of the new drug submission for tafasitamab


12 January 2021 - MorphoSys and Incyte today announced that Health Canada has accepted the new drug submission for tafasitamab, an anti-CD19 antibody.

The application seeks approval of tafasitamab in combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low grade lymphoma, who are not eligible for, or refuse, autologous stem cell transplantation.

Read MorphoSys press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , Canada , Dossier